A recent study showed that the inhibition of CNS c-Abl upon nilotinib treatment reduced Aβ load and tau phosphorylation in AD experimental models and suggested nilotinib as a suitable preclinical candidate for AD therapies [38]. The gene discussed is ABL1; the disease is Alzheimer disease.